Not exact matches
Johns Hopkins Bloomberg School of Public Health researchers say a new
candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children
under the age of one in the U.S.
Although the specific function of the different merozoite surface proteins (MSPs) remains elusive, MSP - 1 and MSP - 3 are currently
under evaluation as
vaccine candidates.
Importantly, this
vaccine candidate is a precursor to
candidates currently
under evaluation for potential testing in West Africa.
The Delta VP30 technology has been approved by the National Institutes of Health for use
under Biosafety Level 2 conditions and has been utilized safely for a decade to study the basic biology of the virus, identify potential antiviral compound
candidates, and make the whole - virus
vaccine.
These events relate primarily to settlement of VaxGen's obligations
under its lease of facilities in South San Francisco, and to the potential award of a procurement contract to Emergent BioSolutions (NYSE: EBS) by the U.S. Government for which VaxGen is eligible to receive milestone and royalty payments in connection with Emergent BioSolutions» May 2008 acquisition of VaxGen's recombinant protective antigen (rPA) anthrax
vaccine product
candidate and related technology.
Under the terms of the sale of its assets and rights relating to its anthrax
vaccine product
candidate and related technology to Emergent BioSolutions Inc, (Emergent), Emergent may be obligated to pay VXGN up to an additional $ 7M in milestone payments, plus specified percentages of future net sales for 12.5 years beginning from the first commercial sale.